[Treatment of patients with destructive pulmonary tuberculosis and nonspecific purulent endobronchitis]. / Lechenie bol'nykh destruktivnym tuberkulezom legkikh i nespetsificheskim gnoinym éndobronkhitom.

Imozymase treatment should be started from the first hospital days in patients with destructive pulmonary tuberculosis concurrent with nonspecific purulent endobronchitis. Two-week ultrasound inhalations with imozymase in a dose of 1 ml (60 PU) may rapidly abolish not only the nonspecific inflammatory bronchial process, but also accelerate the attenuation of symptoms of intoxication, the time of abacillation, cavernous closure, and preparation for surgical interventions.

[Effect of immozymase inhalation on the detection of bacterial discharge in pulmonary tuberculosis]. / Vliianie ingaliatsionnogo vvedeniia immozimazy na vyiavlenie bakteriovydeleniia pri tuberkulëze lëgkikh.

Administration of immosimase, a proteolytic enzyme complex developed in Russia, provoked active Tb discharge when the latter is occult in cases of destructive tuberculosis. Inhalation of the preparation enriches the patients' sputum with the bacilla. This permitted active tuberculosis diagnosis in additional 28% of the examinees.